• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高敏C反应蛋白对支架内再狭窄的长期预后意义。

The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis.

作者信息

Zhu Xinyi, Chen Yuqi, Xiang Li, You Tao, Jiao Yang, Xu Weiting, Chen Jianchang

机构信息

Department of Cardiology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu Province, China.

出版信息

Medicine (Baltimore). 2018 Jul;97(27):e10679. doi: 10.1097/MD.0000000000010679.

DOI:10.1097/MD.0000000000010679
PMID:29979375
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6076028/
Abstract

BACKGROUND

In the current meta-analysis, we aim to assess the effect of high-sensitive C-reactive protein (hs-CRP) on in-stent restenosis (ISR) outcome in patients receiving stent implantation.

METHODS

Embase, PubMed, and Cochrane databases were searched through October 2016 using the keywords "high-sensitive C-reactive protein," "in-stent restenosis." An odds ratio (OR) of on ISR endpoints among patients receiving stent implantation was calculated using random-effects models.

RESULTS

In the meta-analysis of 6 prospective observational studies, there are 1156 coronary heart disease (CHD) patients, a total of 885 stents were implanted and 194 ISR events had been followed up for 6 to 12 months; high-sensitive C-reactive protein levels are associated with the prediction of in-stent restenosis among patients receiving stent implantation. The OR of hs-CRP for ISR was 1.16 [95% confidence interval (CI), 1.01-1.30, P < .05].

CONCLUSIONS

This meta-analysis shows that higher levels of hs-CRP are associated with an increased risk of ISR and indicate a poorer prognosis in CHD patients after stent implantation.

摘要

背景

在当前的荟萃分析中，我们旨在评估高敏C反应蛋白（hs-CRP）对接受支架植入患者支架内再狭窄（ISR）结局的影响。

方法

通过使用关键词“高敏C反应蛋白”、“支架内再狭窄”检索截至2016年10月的Embase、PubMed和Cochrane数据库。使用随机效应模型计算接受支架植入患者中ISR终点的比值比（OR）。

结果

在对6项前瞻性观察性研究的荟萃分析中，有1156例冠心病（CHD）患者，共植入885个支架，194例ISR事件随访6至12个月；高敏C反应蛋白水平与接受支架植入患者的支架内再狭窄预测相关。hs-CRP对ISR的OR为1.16 [95%置信区间（CI），1.01 - 1.30，P<0.05]。

结论

这项荟萃分析表明，较高水平的hs-CRP与ISR风险增加相关，提示冠心病患者支架植入后预后较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/749b4cd5118e/medi-97-e10679-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/0b60c7bd4a00/medi-97-e10679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/25f7a34d9112/medi-97-e10679-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/d4ab050e63db/medi-97-e10679-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/b536fe732256/medi-97-e10679-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/13e1277b81e7/medi-97-e10679-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/749b4cd5118e/medi-97-e10679-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/0b60c7bd4a00/medi-97-e10679-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/25f7a34d9112/medi-97-e10679-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/d4ab050e63db/medi-97-e10679-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/b536fe732256/medi-97-e10679-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/13e1277b81e7/medi-97-e10679-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15d6/6076028/749b4cd5118e/medi-97-e10679-g007.jpg

相似文献

1
The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis.高敏C反应蛋白对支架内再狭窄的长期预后意义。
Medicine (Baltimore). 2018 Jul;97(27):e10679. doi: 10.1097/MD.0000000000010679.
2
Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up.胱抑素C与接受支架植入患者的支架内再狭窄预测相关：1年随访结果
Coron Artery Dis. 2013 Aug;24(5):357-60. doi: 10.1097/MCA.0b013e328361b3a4.
3
Association of high level of hs-CRP with in-stent restenosis: A case-control study.高敏C反应蛋白水平与支架内再狭窄的关联：一项病例对照研究。
Cardiovasc Revasc Med. 2019 Jul;20(7):583-587. doi: 10.1016/j.carrev.2018.08.015. Epub 2018 Aug 18.
4
Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation.m-TOR抑制剂药物洗脱支架植入术后的基线血清C反应蛋白水平与支架内再狭窄模式
J Invasive Cardiol. 2011 Jan;23(1):16-20.
5
Soluble receptor for advanced glycation end products is associated with in-stent restenosis in patients with type 2 diabetes with drug-eluting coronary stents.晚期糖基化终末产物可溶性受体与2型糖尿病患者药物洗脱冠状动脉支架置入术后支架内再狭窄相关。
Coron Artery Dis. 2011 Jan;22(1):12-7. doi: 10.1097/mca.0b013e328340b210.
6
Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.生物可吸收血管支架治疗冠状动脉支架内再狭窄的长期临床结果：意大利多中心经验。
Circ Cardiovasc Interv. 2016 Apr;9(4):e003148. doi: 10.1161/CIRCINTERVENTIONS.115.003148.
7
Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.依维莫司洗脱支架治疗药物洗脱支架与裸金属支架再狭窄的有效性。
Coron Artery Dis. 2012 Nov;23(7):492-6. doi: 10.1097/MCA.0b013e328358a58f.
8
Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.对接受药物洗脱支架植入的经皮冠状动脉介入治疗的冠心病患者快速血管造影狭窄进展和再狭窄风险的预测因素进行综合分析。
J Clin Lab Anal. 2019 Feb;33(2):e22666. doi: 10.1002/jcla.22666. Epub 2018 Sep 17.
9
Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.药物洗脱支架治疗支架内再狭窄的临床结果：前瞻性多中心德国 DES.DE 注册研究第一阶段的结果。
EuroIntervention. 2011 Jun;7(2):201-8. doi: 10.4244/EIJV7I2A34.
10
A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.紫杉醇涂层球囊导管与常规球囊血管成形术治疗金属裸支架再狭窄和药物洗脱支架再狭窄患者的多中心随机比较。
Am Heart J. 2013 Sep;166(3):527-33. doi: 10.1016/j.ahj.2013.07.002. Epub 2013 Aug 13.

引用本文的文献

1
The diagnostic value of long noncoding RNAs as a biomarker for in-stent restenosis in patients with coronary heart disease: A systematic review and meta-analysis of diagnostic test accuracy studies.长链非编码RNA作为冠心病患者支架内再狭窄生物标志物的诊断价值：诊断试验准确性研究的系统评价与荟萃分析
Medicine (Baltimore). 2025 Aug 15;104(33):e43963. doi: 10.1097/MD.0000000000043963.
2
Evaluation of Whole Blood Viscosity to Predict Stent Restenosis in Patients with Coronary Artery Disease.评估全血粘度以预测冠心病患者的支架再狭窄
Anatol J Cardiol. 2025 May 29;29(9):503-11. doi: 10.14744/AnatolJCardiol.2025.5407.
3

本文引用的文献

1
Higher plasma level of STIM1, OPG are correlated with stent restenosis after PCI.STIM1、骨保护素的血浆水平升高与经皮冠状动脉介入治疗（PCI）后的支架再狭窄相关。
Int J Clin Exp Med. 2015 Nov 15;8(11):21089-97. eCollection 2015.
2
Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study.炎症生物标志物与支架内再狭窄组织特征的相关性：一项光学相干断层成像研究。
Eur Heart J Cardiovasc Imaging. 2014 Aug;15(8):917-25. doi: 10.1093/ehjci/jeu035. Epub 2014 Mar 11.
3
The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: insights from a US multicenter registry.
Pre-Percutaneous Coronary Intervention C-Reactive Protein Levels and In-Stent Restenosis: A Systematic Review and Meta-Analysis.
经皮冠状动脉介入治疗前C反应蛋白水平与支架内再狭窄：一项系统评价和Meta分析。
Health Sci Rep. 2025 Apr 29;8(5):e70757. doi: 10.1002/hsr2.70757. eCollection 2025 May.
4
The Diagnostic Value of Circulating Biomarkers and Role of Drug-Coated Balloons for In-Stent Restenosis in Patients with Peripheral Arterial Disease.循环生物标志物对周围动脉疾病患者支架内再狭窄的诊断价值及药物涂层球囊的作用
Diagnostics (Basel). 2022 Sep 12;12(9):2207. doi: 10.3390/diagnostics12092207.
5
Prognostic Value of High-Sensitivity C-Reactive Protein in In-Stent Restenosis: A Meta-Analysis of Clinical Trials.高敏C反应蛋白在支架内再狭窄中的预后价值：临床试验的Meta分析
J Cardiovasc Dev Dis. 2022 Aug 4;9(8):247. doi: 10.3390/jcdd9080247.
6
The Role of Early Revascularization and Biomarkers in the Management of Diabetic Foot Ulcers: A Single Center Experience.早期血运重建和生物标志物在糖尿病足溃疡管理中的作用：单中心经验
Diagnostics (Basel). 2022 Feb 19;12(2):538. doi: 10.3390/diagnostics12020538.
7
Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.糖尿病患者支架内再狭窄的发病机制及临床意义。
Int J Environ Res Public Health. 2021 Nov 15;18(22):11970. doi: 10.3390/ijerph182211970.
8
Association of Kidney Disease, Potassium, and Cardiovascular Risk Factor Prevalence with Coronary Arteriosclerotic Burden, by Sex.按性别划分的肾脏疾病、钾与心血管危险因素患病率与冠状动脉粥样硬化负担的关联
J Pers Med. 2021 Jul 27;11(8):722. doi: 10.3390/jpm11080722.
9
Effects of Altered Levels of Pro- and Anti-Inflammatory Mediators on Locations of In-Stent Reocclusions in Elderly Patients.炎性介质水平变化对老年患者支架再闭塞部位的影响。
Mediators Inflamm. 2020 Sep 23;2020:1719279. doi: 10.1155/2020/1719279. eCollection 2020.
10
Side Effects of Coronary Stenting such as Severe Coronary Stenosis and Multiple Coronary Chronic Total Occlusions in Elderly Patients via Induced Proinflammatory and Prooxidative Stress.老年患者经诱导性促炎和促氧化应激后出现的冠状动脉支架置入术相关副作用，如严重冠状动脉狭窄和多发性冠状动脉慢性完全闭塞。
Mediators Inflamm. 2019 Nov 3;2019:7147652. doi: 10.1155/2019/7147652. eCollection 2019.
“杂交”经皮冠状动脉介入治疗支架内再狭窄所致慢性完全闭塞病变的疗效：来自美国多中心注册研究的见解
Catheter Cardiovasc Interv. 2014 Oct 1;84(4):646-51. doi: 10.1002/ccd.25465. Epub 2014 Jul 4.
4
The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with de novo unprotected distal left main bifurcation coronary lesions: the Milan and New-Tokyo (MITO) Registry.药物洗脱支架植入治疗初发无保护左主干远端分叉冠状动脉病变患者时，主支再狭窄对长期死亡率的影响：米兰和新东京（MITO）注册研究
Catheter Cardiovasc Interv. 2014 Sep 1;84(3):341-8. doi: 10.1002/ccd.25178. Epub 2014 Apr 30.
5
The correlation between early complications of percutaneous coronary intervention and high sensitive C-reactive protein.经皮冠状动脉介入治疗早期并发症与高敏C反应蛋白之间的相关性
ARYA Atheroscler. 2013 Jun;9(4):263-7.
6
Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up.胱抑素C与接受支架植入患者的支架内再狭窄预测相关：1年随访结果
Coron Artery Dis. 2013 Aug;24(5):357-60. doi: 10.1097/MCA.0b013e328361b3a4.
7
Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention.血浆白细胞介素 18、白细胞介素 10、基质金属蛋白酶-9 水平及白细胞介素 18-137G/C 多态性与经皮冠状动脉介入治疗后支架内再狭窄的发生有关。
Inflammation. 2013 Oct;36(5):1129-35. doi: 10.1007/s10753-013-9647-6.
8
Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study.胰岛素与常规治疗对糖尿病患者冠状动脉介入术后再狭窄影响的随机试验。支架再狭窄与代谢（STREAM）研究。
Cardiovasc Revasc Med. 2012 Mar-Apr;13(2):95-100. doi: 10.1016/j.carrev.2011.12.001. Epub 2012 Jan 30.
9
Role of plasma C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting.血浆 C 反应蛋白在预测冠状动脉支架置入术后稳定型心绞痛患者支架内再狭窄中的作用。
Chin Med J (Engl). 2011 Mar;124(6):845-50.
10
Efficacy and safety of drug-eluting stents in patients with acute ST-segment-elevation myocardial infarction: a meta-analysis of randomized controlled trials.药物洗脱支架治疗急性ST段抬高型心肌梗死患者的疗效与安全性：一项随机对照试验的荟萃分析
Tex Heart Inst J. 2010;37(5):516-24.